Literature DB >> 7575676

Antitrypanosomal activity of camptothecin analogs. Structure-activity correlations.

A L Bodley1, M C Wani, M E Wall, T A Shapiro.   

Abstract

African trypanosomes (Trypanosoma brucei species) are parasitic protozoa that cause lethal diseases in humans and cattle. Previous studies showed that camptothecin, a potent and specific inhibitor of DNA topoisomerase I, is cytotoxic to African trypanosomes and related pathogenic hemoflagellates (Bodley AL and Shapiro TA, Proc Natl Acad Sci USA 92: 3726-3730, 1995). In this study, a series of camptothecin analogs was tested against axenically cultured, bloodstream form, T. brucei. Modifications to the pentacyclic nucleus of camptothecin ablated antiparasitic activity. In contrast, activity could be increased by substituents added to the parent ring system (e.g. 10,11-methylenedioxy or ethylenedioxy groups; alkyl additions to carbon 7; or 9-amino or 9-chloro substituents). Cytotoxicity was correlated with the level of cleavable complexes in trypanosomes, implicating topoisomerase I as the intracellular target for these compounds. To obtain some indication of selective toxicity, ten compounds were also tested against L1210 mouse leukemia cells. The 9-substituted-10,11-methylenedioxy analogs caused a disproportionate increase in antiparasitic activity, compared with mammalian cell toxicity. These findings provide a basis for designing further structural modifications and for selecting camptothecin analogs to test in animal models of trypanosomiasis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7575676     DOI: 10.1016/0006-2952(95)00215-l

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  11 in total

1.  Antitrypanosomal activity of fluoroquinolones.

Authors:  E Nenortas; C Burri; T A Shapiro
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

Review 2.  Perspectives on biologically active camptothecin derivatives.

Authors:  Ying-Qian Liu; Wen-Qun Li; Susan L Morris-Natschke; Keduo Qian; Liu Yang; Gao-Xiang Zhu; Xiao-Bing Wu; An-Liang Chen; Shao-Yong Zhang; Xiang Nan; Kuo-Hsiung Lee
Journal:  Med Res Rev       Date:  2015-03-21       Impact factor: 12.944

3.  Antitrypanosomal activities of tryptanthrins.

Authors:  John Scovill; Elizabeth Blank; Michael Konnick; Elizabeth Nenortas; Theresa Shapiro
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

4.  Drug targets in Leishmania.

Authors:  Bhavna Chawla; Rentala Madhubala
Journal:  J Parasit Dis       Date:  2010-10-08

5.  Antitrypanosomal activities of fluoroquinolones with pyrrolidinyl substitutions.

Authors:  Elizabeth Nenortas; Tomasz Kulikowicz; Christian Burri; Theresa A Shapiro
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

6.  Activity of indenoisoquinolines against African trypanosomes.

Authors:  Rahul P Bakshi; Dongpei Sang; Andrew Morrell; Mark Cushman; Theresa A Shapiro
Journal:  Antimicrob Agents Chemother       Date:  2008-09-29       Impact factor: 5.191

7.  An unusual type IB topoisomerase from African trypanosomes.

Authors:  Annette L Bodley; Asit K Chakraborty; Suji Xie; Christian Burri; Theresa A Shapiro
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-16       Impact factor: 11.205

8.  Activity of Aromathecins against African Trypanosomes.

Authors:  Nathaniel P Nenortas; Maris A Cinelli; Andrew E Morrell; Mark Cushman; Theresa A Shapiro
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

9.  Camptothecin nanocolloids based on N,N,N-trimethyl chitosan: efficient suppression of growth of multiple myeloma in a murine model.

Authors:  Zhengguang Li; Xingyi Li; Zhixing Cao; Youzhi Xu; Hongjun Lin; Yinglan Zhao; Yuquan Wei; Zhiyong Qian
Journal:  Oncol Rep       Date:  2012-01-12       Impact factor: 3.906

10.  Trypanothione reductase: a viable chemotherapeutic target for antitrypanosomal and antileishmanial drug design.

Authors:  M Omar F Khan
Journal:  Drug Target Insights       Date:  2007-06-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.